600 patients67,035 observations120 daysLIVE

Patient P-01677

Synthetic patientNBL-101 · Day 101 · 45–54 · F · baseline S15Steering view · 3DOpen companion preview
Is the drug working?

Therapy response 83 at the day-84 endpoint (observed).

Why responding?

Responding: response probability 80%, therapy response 82 today; biology is not blocking the drug.

Is a side effect starting?

Drift detected on day 18 (HRV −25 ms, resting HR +12 bpm, sleep −0.9 h, gi toxicity +57, inflammatory load +40); the side effect would have been reported on day 21 — 3 days of warning.

Still taking it?

7 of 9 scheduled doses in the last 60 days are biologically confirmed (78%); 1 were logged but show no dose signature. Dose signature: resting HR +7 bpm, HRV −6 ms.

last 9 doses · green confirmed · amber logged only · red missed
Plan for this patient
stable, no actionrecommendowner · Companionreview day 108Human Model →
Next action
No action indicated; maintain.
Kept if

Trajectory is stable relative to similar patients; keep the current content.

Daily to-dos in the companion
  • 🍽Keep meals regular; three to four moderate portions spaced through the day
  • 🍽Include a cooked vegetable portion with each main meal
  • Log the daily check-in; one line is enough
  • A 15-minute walk after lunch
  • 💊Take the scheduled dose as agreed with your care team
  • 💊No additional supplements this week
Adherence
89% stable

Adherence is not the problem.

Changes the plan if

sleep quality falling under 35 while GI rises

LLIFE OS insight
grounded · add an LLM key for prose

P-01677 is on day 101 of NBL-101 (EC-02, baseline S15): response declining, tolerance deteriorating, GI deteriorating. Over 14 days response moved -5 and GI +7; discontinuation risk is 30%. The state is in the restoration basin, heading towards failing, after diverging from the model on day 18.

Butyrate capacity 64/100, diversity 3.9, intermediate metabolizer. Pushing it down: Escherichia coli 9.853% (LPS load) (-23.6), Low-HRV stretch (-2.7), Dietary drift (-2.6). Pulling it up: Butyrate producers intact (+10.8).

No action has been tried yet.

No action is indicated now; the trajectory is stable relative to similar patients.

Therapy response
Declining
Tolerance
Deteriorating
GI state
Deteriorating
Inflammatory state
Improving
Nutritional resilience
Favorable
Discontinuation risk
30%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted · dose (weekly infusion, day 1 of each 7-day cycle)
  1. Day 0 NBL-101 startedBaseline state S15
  2. Day 18 Trajectory diverged from predictionObserved response fell below the model's expected path.

What changed?

Trajectory began diverging from predicted response on Day 18.

Primary contributors, last 14 days
  • GI instability+7
  • Inflammatory activity-4
  • Toxicity+4
  • Treatment adherence-2

What helped?

No interventions yet.

    LIFE OS recommendation
    No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.

    Daily trackers

    Asset settings

    The trackers this program marks as important, last 14 days vs the 14 before.

    GI burden
    Companion
    30.5/100
    improving · -1.5 vs previous 14 d
    Toxicity
    Blood
    22.6/100
    worsening · +6.4 vs previous 14 d
    Sleep quality
    Wearable
    51.9/100
    stable · +2.2 vs previous 14 d
    Energy level
    Daily log
    6.5/10
    stable · +0.0 vs previous 14 d
    Stress level
    Daily log
    5.4/10
    worsening · +0.3 vs previous 14 d
    Steps
    Wearable
    3,733
    stable · +157 vs previous 14 d
    Adherence
    Companion
    88.8 %
    stable · -1.7 vs previous 14 d
    This trajectory is decaying — what would help, what would not
    Steering view →

    Heading towards failing · 80 from the failing basin, 15 from restoration.

    Would help
    • No untried action with strong evidence. Compose one from primitives.
    Would not help
    • Nothing clearly counter-productive in the record.
    State influencers · digestive

    Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

    • Spicy / capsaicin
      +2.2no signal · 40%
    • Simple carbohydrates
      -2.1no signal · 39%
    • Insoluble fibre
      -1.6no signal · 32%
    • Alcohol
      +1.3no signal · 27%
    • Dietary fat load
      -1.1no signal · 22%
    • Histamine load
      +0.4no signal · 15%

    DeepGene damage signature

    The metagenomic + host-DNA read-out that initializes this patient's biology and, on retest, measures whether the steering worked.

    Damage score · retest day 90
    32/100
    vs baseline (day 0)
    -14
    6 improved · 0 worsened
    synthetic signature · consistent with this patient's biology
    • 3 opportunists above range: Escherichia coli, Klebsiella pneumoniae, Enterococcus faecium
    • 2 keystone species absent
    • 4 resistance genes
    Pathogens / opportunists3/5
    from 5
    Keystone species2/8
    Diversity0/2
    from 1
    Metabolic modules0/4
    from 1
    Vitamin synthesis1/7
    from 2
    Oral translocation1/1
    Host DNA0/1
    Tissue recycling0/1
    Central mechanisms0/2
    Virulence factors2/2
    Antibiotic resistance genes4/4
    from 5
    Genetic predisposition1/1
    Opportunists above range
    Escherichia coli 9.853% AR
    Enterococcus faecium 4.926% AR
    Klebsiella pneumoniae 2.956% AR
    Keystone species absent
    Akkermansia muciniphila, Bifidobacterium longum
    Capacity
    Shannon 3.15 · butyrate 791 CPM · SCFA 1201
    1 vitamins below
    Host & mechanisms
    tissue recycling 32/100
    oral translocation 2.27% AR
    4 resistance genes · 2 virulence factors

    Biological layers

    Which pathways look influenced, and by which layer of this person's biology.

    Pathways under pressure
    • Autonomic recovery 45
      • WearableResting HR 76 bpm
      • Wearable3,733 steps/day
    • Mucosal barrier integrity 30
      • MicrobiomeAkkermansia low → thinner mucus layer
    • Butyrate / short-chain fatty acid production 25
      • MicrobiomeF. prausnitzii depleted
    • Inflammatory signalling 15
      • WearableHRV 37 ms, trending down
    DNA
    Fictional pharmacogenomic panel
    • CYP2D6 Intermediate metabolizer
      Expected exposure
    Microbiome
    Shannon diversity 3.9 · butyrate capacity 64/100
    • Akkermansia muciniphilaLow
    • Faecalibacterium prausnitziiLow
    • Bacteroides fragilisNormal
    • Bifidobacterium longumLow
    • EnterobacteriaceaeNormal
    Wearable, last 14 days
    daily evolution fed into the runtime
    HRV
    43 ms
    Sleep
    7.8 h
    Steps
    4,161
    Resting HR
    77 bpm
    Daily log: GI score 31, nutritional resilience 62, adherence 89.

    What this patient sees in NostraAI

    The content that steers the trajectory: what to eat, what to do, what to take.

    Open companion preview
    What to eat
    • Keep meals regular; three to four moderate portions spaced through the day
    • Include a cooked vegetable portion with each main meal
    • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
    • Avoid known triggers for now: fried or oily food, dairy, alcohol
    What to do
    • Log the daily check-in; one line is enough
    • A 15-minute walk after lunch
    • Keep the sleep window steady
    • Keep hydration steady: small amounts through the day rather than large volumes at once
    What to take
    • Take the scheduled dose as agreed with your care team
    • No additional supplements this week
    • Fictional demo item: continue vitamin D as before

    284 biologically similar trajectories

    Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

    PatientSimilarityBaselineInterventionOutcomeResponse today
    P-0148132%S15AD-05no change67
    P-0141137%S13BR-03no change76
    P-0176636%S01BR-03improved83
    P-0148935%S05BR-03improved83
    P-0176435%S15BR-03no change85
    P-0189641%S06CR-01improved73
    P-0166438%S07CR-01improved85
    P-0172531%S01CR-01improved62
    P-0142834%S18DT-01improved82
    P-0147233%S20DT-01no change82
    P-0152832%S20DT-01improved89
    P-0134231%S13DT-01improved59